Product Description
Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19239399/)
Mechanisms of Action: DR Agonist,D2 Agonist,D3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Parkinson's Disease|Restless Legs Syndrome
Phase 2: Sleep Apnea, Obstructive|Sleep Bruxism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-001445-13 | P3 |
Completed |
Restless Legs Syndrome |
2023-07-26 |
|
| CTR20221398 | P1 |
Completed |
Parkinson's Disease |
2022-12-12 |
|
| LY03003/CT-CHN-304 | P3 |
Completed |
Parkinson's Disease |
2022-03-17 |
95% |
| STRIVE | P2 |
Active, not recruiting |
Sleep Bruxism|Sleep Apnea, Obstructive |
2021-04-12 |